Icelandic venture capital firm Brunnur Ventures leads funding round to support development of breakthrough lipid nanoparticle delivery technologies ...

SEOUL, South Korea I August 19, 2025 I On August 6, 2025, VASTHERA Co., Ltd. announced that it has received Investigational New Drug (IND) clearance from the ...

Collaboration integrates VantAI’s frontier AI and structural proteomics discovery platform with Halda’s novel and clinically validated RIPTAC™ modality to ...

inMMyCAR is a multi-center Phase 1, open-label, dose-escalation clinical trial designed to assess the safety and preliminary efficacy of a single dose of KLN-1010. The first patient was dosed at Royal ...

Company’s second clinical-stage asset licensed from Mereo Biopharma based on novel insights generated in a mouse model of osteopetrosis - ...

WARREN, NJ, USA I August 19, 2025 I PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a ...

SHANGHAI, China I August 19, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed ...

CAMBRIDGE, MA, USA I August 19, 2025 I XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical ...

AUSTIN, TX, USA I August 19, 2025 I Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class ...

CHICAGO, IL, USA I August 19, 2025 I COUR Pharma, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies to treat ...

A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with ...

U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns ...